There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.

In fact, patients with severe chronic aortic regurgitation may have the largest left ventricular end-diastolic volumes produced by any cardiac disease state, without significant elevation of left ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR ...

A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its Evolut transcatheter aortic valve replacement (TAVR) system delivers durable ...

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, presented results from an expanded cohort of 500 patients in the ALIGN-AR Pivotal Trial ...

Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its first-ever Transcatheter Aortic Valve Replacement (TAVR) procedure.